Hoh Brian L, Rabinov James D, Pryor Johnny C, Carter Bob S, Barker Fred G
Neurosurgical Service, Massachusetts General Hospital, Boston, MA 02114, USA.
AJNR Am J Neuroradiol. 2003 Aug;24(7):1409-20.
Endovascular therapy is increasingly being used for the treatment of unruptured intracranial aneurysms. Our purpose was to determine the risk of adverse outcomes after contemporary endovascular treatment of unruptured intracranial aneurysms in the United States. Patient, treating physician, and hospital characteristics were tested as potential outcome predictors, with particular attention paid to volume of care.
We conducted a retrospective cohort study by using the Nationwide Inpatient Sample, 1996-2000. Multivariate logistic and ordinal regressions were used with end points of mortality, discharge other than to home, length of stay, and total hospital charges.
Four hundred twenty-one patients underwent endovascular treatment at 81 hospitals. The in-hospital mortality rate was 1.7%, and 7.6% were discharged to institutions other than home. Analysis was adjusted for age, sex, race, primary payer, year of treatment, and four variables measuring acuity of treatment and medical comorbidity. Median annual number of unruptured aneurysms treated was nine per hospital and three per treating physician. Higher volume hospitals had fewer adverse outcomes; discharge other than to home occurred after 5.2% of operations at high volume hospitals (>23 admissions per year) compared with 17.6% at low volume hospitals (fewer than four admissions per year) (P<.001). Higher physician volume had a similar effect (0% versus 16.4%, P=.03). The mortality rate was lower at high volume hospitals (1.0% versus 3.7%) but not significantly so. At high volume hospitals, length of stay was shorter (P<.001) and total hospital charges were lower (P<.001).
For patients with unruptured aneurysms treated in the United States from 1996 to 2000, endovascular treatment at high volume institutions or by high volume physicians was associated with significantly lower morbidity rates and modestly lower mortality rates. Length of stay was shorter and total hospital charges lower at high volume centers.
血管内治疗越来越多地用于未破裂颅内动脉瘤的治疗。我们的目的是确定在美国对未破裂颅内动脉瘤进行当代血管内治疗后不良后果的风险。对患者、治疗医师和医院特征作为潜在结局预测因素进行了测试,特别关注治疗量。
我们使用1996 - 2000年全国住院患者样本进行了一项回顾性队列研究。使用多变量逻辑回归和有序回归,以死亡率、非回家出院、住院时间和总住院费用作为终点。
81家医院的421例患者接受了血管内治疗。院内死亡率为1.7%,7.6%的患者出院时未回家而是前往其他机构。分析对年龄、性别、种族、主要支付方、治疗年份以及四个衡量治疗敏锐度和医疗合并症的变量进行了调整。每家医院每年治疗未破裂动脉瘤的中位数为9例,每位治疗医师每年治疗3例。治疗量较高的医院不良后果较少;高治疗量医院(每年入院>23例)5.2%的手术患者出现非回家出院,而低治疗量医院(每年入院少于4例)这一比例为17.6%(P<0.001)。医师治疗量较高也有类似效果(0%对16.4%,P = 0.03)。高治疗量医院的死亡率较低(1.0%对3.7%),但差异无统计学意义。在高治疗量医院,住院时间较短(P<0.001),总住院费用较低(P<0.001)。
对于1996年至2000年在美国接受治疗的未破裂动脉瘤患者,在高治疗量机构或由高治疗量医师进行血管内治疗与显著较低的发病率和适度较低的死亡率相关。高治疗量中心的住院时间较短,总住院费用较低。